<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00174941</url>
  </required_header>
  <id_info>
    <org_study_id>TMX-01-005</org_study_id>
    <secondary_id>U1111-1114-2039</secondary_id>
    <nct_id>NCT00174941</nct_id>
  </id_info>
  <brief_title>Long-Term Safety of Febuxostat in Subjects With Gout.</brief_title>
  <acronym>FOCUS</acronym>
  <official_title>Phase II, Open-Label Study, to Assess the Long-Term Safety of Oral TMX-67 in Subjects With Gout</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term safety of febuxostat, once daily (QD),
      in maintaining serum urate levels within clinically acceptable levels in subjects with gout.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uric acid is the end product of purine degradation in humans. Hyperuricemia, a urate
      concentration in serum exceeding the limit of urate solubility (approximately 7.0 milligrams
      per deciliter [mg/dL]), is a common biochemical abnormality. Aberrations in any of the
      multiple mechanisms involved in the production and/or excretion of uric acid may increase
      serum urate concentrations, with persistent hyperuricemia as a marker for extracellular fluid
      monosodium urate supersaturation. As such, hyperuricemia is a necessary (but often not
      sufficient) risk factor for monosodium urate crystal deposition in tissues and is the
      fundamental pathophysiological process underlying the clinical manifestations of gout, which
      is a chronic disease characterized by urate crystal formation and deposition in joints and
      bones. Gout may progress from episodic attacks of acute inflammatory arthritis to a disabling
      chronic disorder characterized by deforming arthropathy; destructive deposits of urate
      crystals (tophi) in bones, joints, and other organs; structural and functional renal
      impairment due to interstitial urate crystal deposition; and urinary tract stones composed
      entirely or in part of uric acid crystals. Management of gout requires chronic treatment
      aimed at lowering serum urate into a subsaturating range (usually &lt;6.0 mg/dL) in which
      crystal formation and deposition are prevented or reversed.

      Febuxostat (TMX-67) is a non-purine selective xanthine oxidase inhibitor being developed as
      an orally administered agent for management of hyperuricemia in patients with gout.

      Subjects who want to participate in this study will have successfully completed study
      TMX-00-004 (NCT00174967).

      All participants will initially receive an 80 mg dose. Dose titrations will occur in order to
      obtain and maintain clinically acceptable serum urate levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2001</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at &lt;6.0 mg/dL at Month 6 Visit.</measure>
    <time_frame>Month 6</time_frame>
    <description>Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 6 visit was summarized.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at &lt;6.0 mg/dL at Month 12 Visit.</measure>
    <time_frame>Month 12</time_frame>
    <description>Serum urate values were obtained at the Month 12 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 12 visit was summarized.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at &lt;6.0 mg/dL at Month 18 Visit.</measure>
    <time_frame>Month 18</time_frame>
    <description>Serum urate values were obtained at the Month 18 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 18 visit was summarized.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at &lt;6.0 mg/dL at Month 24 Visit.</measure>
    <time_frame>Month 24</time_frame>
    <description>Serum urate values were obtained at the Month 24 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 24 visit was summarized.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at &lt;6.0 mg/dL at Month 36 Visit.</measure>
    <time_frame>Month 36</time_frame>
    <description>Serum urate values were obtained at the Month 36 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 36 visit was summarized.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at &lt;6.0 mg/dL at Month 48 Visit.</measure>
    <time_frame>Month 48</time_frame>
    <description>Serum urate values were obtained at the Month 48 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 48 visit was summarized.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at &lt;6.0 mg/dL at Month 60 Visit.</measure>
    <time_frame>Month 60</time_frame>
    <description>Serum urate values were obtained at the Month 60 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 60 visit was summarized.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at &lt;6.0 mg/dL at Final Visit.</measure>
    <time_frame>Last Visit on treatment (up to 66 months).</time_frame>
    <description>The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Serum Urate Levels From Baseline at Month 6 Visit.</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>Serum urate values were obtained at the Month 6 visit. The percent change in serum urate from baseline to the Month 6 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Serum Urate Levels From Baseline at Month 12 Visit.</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Serum urate values were obtained at the Month 12 visit. The percent change in serum urate from baseline to the Month 12 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Serum Urate Levels From Baseline at Month 18 Visit.</measure>
    <time_frame>Baseline and Month 18</time_frame>
    <description>Serum urate values were obtained at the Month 18 visit. The percent change in serum urate from baseline to the Month 18 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Serum Urate Levels From Baseline at Month 24 Visit.</measure>
    <time_frame>Baseline and Month 24</time_frame>
    <description>Serum urate values were obtained at the Month 24 visit. The percent change in serum urate from baseline to the Month 24 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Serum Urate Levels From Baseline at Month 36 Visit.</measure>
    <time_frame>Baseline and Month 36</time_frame>
    <description>Serum urate values were obtained at the Month 36 visit. The percent change in serum urate from baseline to the Month 36 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Serum Urate Levels From Baseline at Month 48 Visit.</measure>
    <time_frame>Baseline and Month 48</time_frame>
    <description>Serum urate values were obtained at the Month 48 visit. The percent change in serum urate from baseline to the Month 48 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Serum Urate Levels From Baseline at Month 60 Visit.</measure>
    <time_frame>Baseline and Month 60</time_frame>
    <description>The secondary outcome was the mean percent change from baseline to Month 60 visit as assessed by serum urate levels collected at baseline and at the Month 60 visit by dose at observation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Serum Urate Levels From Baseline at Final Visit.</measure>
    <time_frame>Baseline and Last Visit on treatment (up to 66 months).</time_frame>
    <description>The percent change in serum urate from baseline to the final visit was summarized. The final visit was the last visit at which a serum urate value was collected.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>Febuxostat 40 mg, tablets, orally, once daily, based on serum urate level.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>TMX-67</other_name>
    <other_name>Tei-6720</other_name>
    <other_name>Uloric</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>Febuxostat 80 mg, tablets, orally, once daily, based on serum urate level.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>TMX-67</other_name>
    <other_name>Tei-6720</other_name>
    <other_name>Uloric</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>Febuxostat 120 mg, tablets, orally, once daily, based on serum urate level.</description>
    <arm_group_label>3</arm_group_label>
    <other_name>TMX-67</other_name>
    <other_name>Tei-6720</other_name>
    <other_name>Uloric</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hyperuricemia (serum uric acid ≥8.0 mg/dL upon entering parent study TMX-00-004).

          -  Must meet American College of Rheumatology criteria for gout.

          -  Must have adequate renal function (serum creatinine &lt;1.5 mg/dL).

          -  Must have completed four weeks of double-blind dosing in Study TMX-00-004.

          -  Must not have experienced any serious study drug-related Adverse Events in Study TMX
             00-004.

          -  Females of childbearing potential who are sexually active must agree to use adequate
             contraception, and can neither be pregnant nor lactating from Screening throughout the
             duration of the study.

        Exclusion Criteria:

          -  History of xanthinuria

          -  Alcohol consumption &gt;14/week

          -  Has a History of significant concomitant illness

          -  Has active liver disease.

          -  Has a body mass index greater than 50 kg/m2

          -  Any other significant medical condition that would interfere with the treatment,
             safety or compliance with the protocol, as defined by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Chair</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <link>
    <url>http://general.takedapharm.com/content/file.aspx?applicationcode=6C7C39D8-5D09-453B-BF30-696A4AB88E62&amp;fileTypeCode=ULORICPI</url>
    <description>Uloric Package Insert</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <results_reference>
    <citation>Colwell HH, Hunt BJ, Pasta DJ, Palo WA, Mathias SD, Joseph-Ridge N. Gout Assessment Questionnaire: Initial results of reliability, validity and responsiveness. Int J Clin Pract. 2006 Oct;60(10):1210-7. Epub 2006 Aug 15.</citation>
    <PMID>16911575</PMID>
  </results_reference>
  <results_reference>
    <citation>Schumacher HR Jr, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009 Feb;48(2):188-94. doi: 10.1093/rheumatology/ken457.</citation>
    <PMID>19141576</PMID>
  </results_reference>
  <results_reference>
    <citation>Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol. 2011 Jan;17(1):7-13. doi: 10.1097/RHU.0b013e318204aab4.</citation>
    <PMID>21169856</PMID>
  </results_reference>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>March 12, 2009</results_first_submitted>
  <results_first_submitted_qc>May 26, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2009</results_first_posted>
  <last_update_submitted>January 25, 2011</last_update_submitted>
  <last_update_submitted_qc>January 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Sr. VP, Clinical Science</name_title>
    <organization>Takeda Global Research &amp; Development Center, Inc.</organization>
  </responsible_party>
  <keyword>Uric acid</keyword>
  <keyword>xanthine oxidase</keyword>
  <keyword>tophi</keyword>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled at 23 investigational sites in the United States from 21 March 2001 to 29 December 2006</recruitment_details>
      <pre_assignment_details>Subjects were to have completed 4 weeks of double-blind dosing in Study TMX-00-004 (NCT00174967) before enrollment in once daily (QD) treatment groups. Dose titrations will occur in order to obtain and maintain clinically acceptable serum urate levels.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Febuxostat 40 mg QD</title>
          <description>Febuxostat 40 mg, orally, once daily, based on serum urate level.</description>
        </group>
        <group group_id="P2">
          <title>Febuxostat 80 mg QD</title>
          <description>Febuxostat 80 mg, orally, once daily, based on serum urate level.</description>
        </group>
        <group group_id="P3">
          <title>Febuxostat 120 mg QD</title>
          <description>Febuxostat 120 mg, orally, once daily, based on serum urate level.</description>
        </group>
        <group group_id="P4">
          <title>Total Febuxostat</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8">Subjects started on febuxostat 80mg. Number of subjects based on Final Stable Dose after titration.</participants>
                <participants group_id="P2" count="79">Subjects started on febuxostat 80mg. Number of subjects based on Final Stable Dose after titration.</participants>
                <participants group_id="P3" count="29">Subjects started on febuxostat 80mg. Number of subjects based on Final Stable Dose after titration.</participants>
                <participants group_id="P4" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="58"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal Reason(s)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Gout Flare</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Febuxostat 40 mg QD</title>
          <description>Febuxostat 40 mg orally, once daily, based on serum urate level.</description>
        </group>
        <group group_id="B2">
          <title>Febuxostat 80 mg QD</title>
          <description>Febuxostat 80 mg, orally, once daily, based on serum urate level</description>
        </group>
        <group group_id="B3">
          <title>Febuxostat 120 mg QD</title>
          <description>Febuxostat 120 mg, orally, once daily, based on serum urate level</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="79"/>
            <count group_id="B3" value="29"/>
            <count group_id="B4" value="116"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 to &lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.5" spread="11.44"/>
                    <measurement group_id="B2" value="53.9" spread="12.85"/>
                    <measurement group_id="B3" value="51.3" spread="13.01"/>
                    <measurement group_id="B4" value="53.3" spread="12.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="105.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Kidney Stone</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Presence of Tophus</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Renal Function</title>
          <description>Impaired renal function was defined as serum creatinine &gt;1.5 milligrams per deciliter (mg/dL) or a creatinine clearance of ≤80 milliliters per minute (mL/min)</description>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impaired</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urine Uric Acid</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Underexcretor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overproducer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kiligram per meter² (kg/m²)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.4" spread="2.78"/>
                    <measurement group_id="B2" value="32.9" spread="5.28"/>
                    <measurement group_id="B3" value="33.9" spread="6.82"/>
                    <measurement group_id="B4" value="32.9" spread="5.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Urate</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.58" spread="1.18"/>
                    <measurement group_id="B2" value="9.48" spread="1.04"/>
                    <measurement group_id="B3" value="10.23" spread="1.74"/>
                    <measurement group_id="B4" value="9.7" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at &lt;6.0 mg/dL at Month 6 Visit.</title>
        <description>Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 6 visit was summarized.</description>
        <time_frame>Month 6</time_frame>
        <population>Subjects with a serum urate value at the Month 6 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 6 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O3">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O4">
            <title>Total Febuxostat</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at &lt;6.0 mg/dL at Month 6 Visit.</title>
          <description>Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 6 visit was summarized.</description>
          <population>Subjects with a serum urate value at the Month 6 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 6 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="65"/>
                    <measurement group_id="O4" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Serum Urate Levels From Baseline at Month 6 Visit.</title>
        <description>Serum urate values were obtained at the Month 6 visit. The percent change in serum urate from baseline to the Month 6 visit was summarized.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>Subjects with a serum urate value at the Month 6 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 6 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O3">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O4">
            <title>Total Febuxostat</title>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Serum Urate Levels From Baseline at Month 6 Visit.</title>
          <description>Serum urate values were obtained at the Month 6 visit. The percent change in serum urate from baseline to the Month 6 visit was summarized.</description>
          <population>Subjects with a serum urate value at the Month 6 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 6 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.9" spread="9.55"/>
                    <measurement group_id="O2" value="-50.6" spread="9.84"/>
                    <measurement group_id="O3" value="-47.6" spread="19.6"/>
                    <measurement group_id="O4" value="-48.3" spread="13.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at &lt;6.0 mg/dL at Month 12 Visit.</title>
        <description>Serum urate values were obtained at the Month 12 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 12 visit was summarized.</description>
        <time_frame>Month 12</time_frame>
        <population>Subjects with a serum urate value at the Month 12 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 12 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O3">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O4">
            <title>Total Febuxostat</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at &lt;6.0 mg/dL at Month 12 Visit.</title>
          <description>Serum urate values were obtained at the Month 12 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 12 visit was summarized.</description>
          <population>Subjects with a serum urate value at the Month 12 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 12 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at &lt;6.0 mg/dL at Month 18 Visit.</title>
        <description>Serum urate values were obtained at the Month 18 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 18 visit was summarized.</description>
        <time_frame>Month 18</time_frame>
        <population>Subjects with a serum urate value at the Month 18 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 18 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O3">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O4">
            <title>Total Febuxostat</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at &lt;6.0 mg/dL at Month 18 Visit.</title>
          <description>Serum urate values were obtained at the Month 18 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 18 visit was summarized.</description>
          <population>Subjects with a serum urate value at the Month 18 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 18 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at &lt;6.0 mg/dL at Month 24 Visit.</title>
        <description>Serum urate values were obtained at the Month 24 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 24 visit was summarized.</description>
        <time_frame>Month 24</time_frame>
        <population>Subjects with a serum urate value at the Month 24 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 24 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O3">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O4">
            <title>Total Febuxostat</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at &lt;6.0 mg/dL at Month 24 Visit.</title>
          <description>Serum urate values were obtained at the Month 24 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 24 visit was summarized.</description>
          <population>Subjects with a serum urate value at the Month 24 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 24 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="92"/>
                    <measurement group_id="O4" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at &lt;6.0 mg/dL at Month 36 Visit.</title>
        <description>Serum urate values were obtained at the Month 36 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 36 visit was summarized.</description>
        <time_frame>Month 36</time_frame>
        <population>Subjects with a serum urate value at the Month 36 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 36 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O3">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O4">
            <title>Total Febuxostat</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at &lt;6.0 mg/dL at Month 36 Visit.</title>
          <description>Serum urate values were obtained at the Month 36 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 36 visit was summarized.</description>
          <population>Subjects with a serum urate value at the Month 36 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 36 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="92"/>
                    <measurement group_id="O4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at &lt;6.0 mg/dL at Month 48 Visit.</title>
        <description>Serum urate values were obtained at the Month 48 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 48 visit was summarized.</description>
        <time_frame>Month 48</time_frame>
        <population>Subjects with a serum urate value at the Month 48 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 48 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O3">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O4">
            <title>Total Febuxostat</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at &lt;6.0 mg/dL at Month 48 Visit.</title>
          <description>Serum urate values were obtained at the Month 48 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 48 visit was summarized.</description>
          <population>Subjects with a serum urate value at the Month 48 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 48 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="85"/>
                    <measurement group_id="O4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at &lt;6.0 mg/dL at Month 60 Visit.</title>
        <description>Serum urate values were obtained at the Month 60 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 60 visit was summarized.</description>
        <time_frame>Month 60</time_frame>
        <population>Subjects with a serum urate value at the Month 60 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 60 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O3">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O4">
            <title>Total Febuxostat</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at &lt;6.0 mg/dL at Month 60 Visit.</title>
          <description>Serum urate values were obtained at the Month 60 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Month 60 visit was summarized.</description>
          <population>Subjects with a serum urate value at the Month 60 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 60 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="91"/>
                    <measurement group_id="O4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at &lt;6.0 mg/dL at Final Visit.</title>
        <description>The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected.</description>
        <time_frame>Last Visit on treatment (up to 66 months).</time_frame>
        <population>Two subjects who did not have any post-baseline Serum Urate Level measurements were excluded from this analysis. Results were summarized by the dose the subject was receiving at the time of the final visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O3">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O4">
            <title>Total Febuxostat</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at &lt;6.0 mg/dL at Final Visit.</title>
          <description>The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected.</description>
          <population>Two subjects who did not have any post-baseline Serum Urate Level measurements were excluded from this analysis. Results were summarized by the dose the subject was receiving at the time of the final visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="81"/>
                    <measurement group_id="O4" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Serum Urate Levels From Baseline at Month 12 Visit.</title>
        <description>Serum urate values were obtained at the Month 12 visit. The percent change in serum urate from baseline to the Month 12 visit was summarized.</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Subjects with a serum urate value at the Month 12 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 12 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O3">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O4">
            <title>Total Febuxostat</title>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Serum Urate Levels From Baseline at Month 12 Visit.</title>
          <description>Serum urate values were obtained at the Month 12 visit. The percent change in serum urate from baseline to the Month 12 visit was summarized.</description>
          <population>Subjects with a serum urate value at the Month 12 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 12 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
          <units>percentage of subjects</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.0" spread="13.16"/>
                    <measurement group_id="O2" value="-49.7" spread="9.26"/>
                    <measurement group_id="O3" value="-49.3" spread="15.77"/>
                    <measurement group_id="O4" value="-48.3" spread="11.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Serum Urate Levels From Baseline at Month 18 Visit.</title>
        <description>Serum urate values were obtained at the Month 18 visit. The percent change in serum urate from baseline to the Month 18 visit was summarized.</description>
        <time_frame>Baseline and Month 18</time_frame>
        <population>Subjects with a serum urate value at the Month 18 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 18 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O3">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O4">
            <title>Total Febuxostat</title>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Serum Urate Levels From Baseline at Month 18 Visit.</title>
          <description>Serum urate values were obtained at the Month 18 visit. The percent change in serum urate from baseline to the Month 18 visit was summarized.</description>
          <population>Subjects with a serum urate value at the Month 18 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 18 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.5" spread="16.35"/>
                    <measurement group_id="O2" value="-48.7" spread="11.12"/>
                    <measurement group_id="O3" value="-39.5" spread="19.36"/>
                    <measurement group_id="O4" value="-45.4" spread="14.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Serum Urate Levels From Baseline at Month 24 Visit.</title>
        <description>Serum urate values were obtained at the Month 24 visit. The percent change in serum urate from baseline to the Month 24 visit was summarized.</description>
        <time_frame>Baseline and Month 24</time_frame>
        <population>Subjects with a serum urate value at the Month 24 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 24 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O3">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O4">
            <title>Total Febuxostat</title>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Serum Urate Levels From Baseline at Month 24 Visit.</title>
          <description>Serum urate values were obtained at the Month 24 visit. The percent change in serum urate from baseline to the Month 24 visit was summarized.</description>
          <population>Subjects with a serum urate value at the Month 24 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 24 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.9" spread="19.41"/>
                    <measurement group_id="O2" value="-46.7" spread="11.59"/>
                    <measurement group_id="O3" value="-54.7" spread="12.02"/>
                    <measurement group_id="O4" value="-47.3" spread="13.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Serum Urate Levels From Baseline at Month 36 Visit.</title>
        <description>Serum urate values were obtained at the Month 36 visit. The percent change in serum urate from baseline to the Month 36 visit was summarized.</description>
        <time_frame>Baseline and Month 36</time_frame>
        <population>Subjects with a serum urate value at the Month 36 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 36 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O3">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O4">
            <title>Total Febuxostat</title>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Serum Urate Levels From Baseline at Month 36 Visit.</title>
          <description>Serum urate values were obtained at the Month 36 visit. The percent change in serum urate from baseline to the Month 36 visit was summarized.</description>
          <population>Subjects with a serum urate value at the Month 36 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 36 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.0" spread="9.14"/>
                    <measurement group_id="O2" value="-46.9" spread="13.35"/>
                    <measurement group_id="O3" value="-56.4" spread="13.76"/>
                    <measurement group_id="O4" value="-48.4" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Serum Urate Levels From Baseline at Month 48 Visit.</title>
        <description>Serum urate values were obtained at the Month 48 visit. The percent change in serum urate from baseline to the Month 48 visit was summarized.</description>
        <time_frame>Baseline and Month 48</time_frame>
        <population>Subjects with a serum urate value at the Month 48 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 48 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O3">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O4">
            <title>Total Febuxostat</title>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Serum Urate Levels From Baseline at Month 48 Visit.</title>
          <description>Serum urate values were obtained at the Month 48 visit. The percent change in serum urate from baseline to the Month 48 visit was summarized.</description>
          <population>Subjects with a serum urate value at the Month 48 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 48 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.0" spread="4.16"/>
                    <measurement group_id="O2" value="-50.3" spread="10.61"/>
                    <measurement group_id="O3" value="-53.8" spread="16.41"/>
                    <measurement group_id="O4" value="-51.1" spread="11.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Serum Urate Levels From Baseline at Month 60 Visit.</title>
        <description>The secondary outcome was the mean percent change from baseline to Month 60 visit as assessed by serum urate levels collected at baseline and at the Month 60 visit by dose at observation.</description>
        <time_frame>Baseline and Month 60</time_frame>
        <population>Subjects with a serum urate value at the Month 60 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 60 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O3">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O4">
            <title>Total Febuxostat</title>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Serum Urate Levels From Baseline at Month 60 Visit.</title>
          <description>The secondary outcome was the mean percent change from baseline to Month 60 visit as assessed by serum urate levels collected at baseline and at the Month 60 visit by dose at observation.</description>
          <population>Subjects with a serum urate value at the Month 60 visit were included in the analysis. Results were summarized by the dose the subject was receiving at the Month 60 visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.5" spread="8.70"/>
                    <measurement group_id="O2" value="-51.1" spread="13.21"/>
                    <measurement group_id="O3" value="-59.0" spread="18.74"/>
                    <measurement group_id="O4" value="-52.0" spread="14.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Serum Urate Levels From Baseline at Final Visit.</title>
        <description>The percent change in serum urate from baseline to the final visit was summarized. The final visit was the last visit at which a serum urate value was collected.</description>
        <time_frame>Baseline and Last Visit on treatment (up to 66 months).</time_frame>
        <population>Two subjects who did not have any post-baseline Serum Urate Level measurements were excluded from this analysis. Results were summarized by the dose the subject was receiving at the time of the final visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O3">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily, based on serum urate level.</description>
          </group>
          <group group_id="O4">
            <title>Total Febuxostat</title>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Serum Urate Levels From Baseline at Final Visit.</title>
          <description>The percent change in serum urate from baseline to the final visit was summarized. The final visit was the last visit at which a serum urate value was collected.</description>
          <population>Two subjects who did not have any post-baseline Serum Urate Level measurements were excluded from this analysis. Results were summarized by the dose the subject was receiving at the time of the final visit. Subjects must have been receiving that dose for at least 14 days prior to the visit.</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.2" spread="7.10"/>
                    <measurement group_id="O2" value="-47.1" spread="16.42"/>
                    <measurement group_id="O3" value="-50.7" spread="19.12"/>
                    <measurement group_id="O4" value="-48.1" spread="16.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Febuxostat 40 mg QD</title>
          <description>Febuxostat 40 mg taken orally, once daily, based on serum urate level.</description>
        </group>
        <group group_id="E2">
          <title>Febuxostat 80 mg QD</title>
          <description>Febuxostat 80 mg, taken orally, once daily, based on serum urate level</description>
        </group>
        <group group_id="E3">
          <title>Febuxostat 120 mg QD</title>
          <description>Febuxostat 120 mg, taken orally, once daily, based on serum urate level</description>
        </group>
        <group group_id="E4">
          <title>Febuxostat Total</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Conduction Disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Supraventricular Arrhythmias</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal and Small Intestinal Stenosis and Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Ulcers and Perforation, Site Unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Intestinal Ulcers &amp; Perforation not elsewhere classified (NEC)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain and Discomfort NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis and Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal and Gastrointestinal Infections</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract and Lung Infections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Sepsis, Bacteraemia, Viraemia, and Infections</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cerebral Injuries NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Fractures and Dislocations NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Non-Site Specific Injuries NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Radiation Injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral Disc Disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Joint Related Disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Osteoarthropathies</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Pathological Fractures and Complications</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Spine and Neck Deformities</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lip and Oral Cavity Neoplasms Malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Prostatic Neoplasms Malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Respiratory Tract and Pleural Neoplasms Benign NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Skin Neoplasms Malignant &amp; Unspecified (Excluding Melanoma)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Alzheimer's Disease (Including Subtypes)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Central Nervous System Hemorrhages &amp; Cerebrovascular Accidents</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depressive Disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder and Urethral Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Atonic and Hypomotility Disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Signs and Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Nausea and Vomiting Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin Injuries NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver Function Analyses</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>White Blood Cell Analyses</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Triglyceride Analyses</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Blood Amylase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Weight Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Blood Thyroid Stimulating Hormone Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipidaemias NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Related Signs and Symptoms NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Arthropathies</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Joint Related Signs and Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Muscle Pains</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and Connective Tissue Signs and Symptoms NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headaches NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Lithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rashes, Eruptions and Exanthems</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr VP, Clinical Science</name_or_title>
      <organization>Takeda Global Research &amp; Development Center, Inc.</organization>
      <phone>800-778-2860</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

